Education
About Us
Working with TipRanks
Follow Us
Idorsia Ltd (CH:IDIA)
:IDIA
Top Page
Idorsia Ltd
(IDIA)
Select Model
Select Model
Rating:45Neutral
Price Target:
CHF3.00
▼(-4.46% Downside)
Action:ReiteratedDate:03/08/26
The score is held down primarily by a fragile capital structure (high debt vs assets and negative equity) and still-negative cash generation despite improving burn. The latest earnings call is a clear positive with stronger QUVIVIQ traction, cost discipline, and constructive 2026 guidance, but key near-term execution and regulatory uncertainties remain. Technically, the stock shows weak near-term trend signals with only limited support from oversold momentum readings.
Positive Factors
Strong QUVIVIQ commercial traction
Rapid, sustained uptake of QUVIVIQ and management guidance to CHF 200M in 2026 indicate durable commercial product-market fit. Reimbursement wins and geographic expansion (EUCAN strength, China uptake) reduce single-market dependence and support a multi-quarter path to positive commercial contribution and scaled revenue.
Material cost cuts and improving margins
Significant cost savings and a much narrower operating loss show better cost discipline and scalable expense control. Flat OpEx guidance against growing sales implies operating leverage, improving margin sustainability and narrowing the path to cash‑flow breakeven over the next several quarters.
Regulatory approvals and differentiated pipeline
Regulatory approvals, guideline inclusion and a strong pivotal efficacy signal materially de‑risk TRYVIO's commercial prospects. Coupled with lucerastat's agreed path with regulators and multiple clinical starts, the pipeline provides multi-year upside and reduces reliance on a single product for long‑term growth.
Negative Factors
High leverage and negative equity
A stretched capital structure with high debt and deeply negative equity weakens financial flexibility. Persistent negative equity increases refinancing, covenant and counterparty risks, reducing the company’s ability to absorb shocks or fund simultaneous commercialization and R&D needs without dilutive or costly financing.
Ongoing negative operating cash flow
Although cash burn has improved materially, recurring negative operating cash flow means the business remains dependent on external funding. This structural reliance elevates dilution or refinancing risk and constrains long‑term investment choices, especially if commercial or partnership milestones slip.
U.S. access and partnership execution uncertainty
Key growth drivers hinge on regulatory outcomes and deal execution. U.S. descheduling uncertainty limits pharmacy access and national uptake, while an unfinished TRYVIO commercialization partnership leaves scaling dependent on future agreements. Both factors create multi‑quarter commercialization execution risk.
Idorsia Ltd (IDIA) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF788.18M
Dividend YieldN/A
Average Volume (3M)2.48M
Price to Earnings (P/E)―
Beta (1Y)1.96
Revenue Growth229.23%
EPS Growth63.47%
CountryCH
Employees636
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.27
Shares Outstanding252,461,100
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.75Price Target Upside51.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.48
Revenue Forecast (FY)CHF226.37M
Idorsia Ltd Business Overview & Revenue Model
Company DescriptionIdorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
How the Company Makes MoneyIdorsia makes money primarily through (1) net product sales of its approved medicine QUVIVIQ (daridorexant), where revenue is recognized from selling the product into distribution channels (e.g., wholesalers/distributors) in markets where it is commercialized; and (2) collaboration-related income, which can include upfront payments, milestone payments tied to development/regulatory/commercial events, and royalties on partners’ sales when Idorsia out-licenses products or regional commercialization rights. The relative contribution of these streams depends on the scale of QUVIVIQ’s commercial uptake and the timing/terms of partnering transactions. Specific, current partnership counterparties and exact deal economics: null.
Idorsia Ltd Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 28, 2026
Earnings Call Sentiment Positive
The call communicated a clear operational turnaround: materially stronger commercial traction (QUVIVIQ sales > doubled, EUCAN strength), significant cost savings, improved operating losses and strengthened liquidity. These positives are balanced by remaining profitability gaps, U.S. access/regulatory uncertainty for QUVIVIQ (descheduling pending), an unfinished TRYVIO commercialization partnership process, and multi‑year timelines for key pipeline readouts (e.g., lucerastat). On balance, the company presented meaningful progress and a credible path to further de‑risking and growth, while acknowledging key near‑term risks tied to partnerships, U.S. regulatory outcomes and cash runway beyond the next inflection points.Q4-2025 Updates
Positive Updates
QUVIVIQ Sales More Than Doubled
QUVIVIQ product sales increased from ~CHF 60–61 million in 2024 to CHF 134 million in 2025 (≈+123%), driving net revenue to CHF 214 million and exceeding the upgraded 2025 guidance (guided CHF 130 million). Company guides QUVIVIQ sales of ~CHF 200 million for 2026 (≈+49% vs 2025).
Strong Regional EUCAN Growth
EUCAN sales rose from CHF 32 million to CHF 108 million in 2025 (≈+238%), cited as the main driver of the QUVIVIQ sales increase.
Marked Improvement in Operational Losses
Non‑GAAP operating loss improved from CHF -308 million in 2024 to CHF -100 million in 2025, a reduction in loss of CHF 208 million (≈67.5% improvement). U.S. GAAP EBIT loss narrowed to CHF -33 million.
Liquidity Strengthened and Funding Secured
Year-end liquidity comprised CHF 89 million cash on hand plus access to CHF 80 million from a new money facility (total available liquidity CHF 169 million). Secured a CHF 150 million funding facility, drew CHF 70 million, and raised CHF 68 million net via equity.
Material Cost Savings and Balance Sheet Improvements
Cost rationalization delivered savings of >CHF 80 million versus 2024. Negotiations reduced Idorsia's cost-sharing commitments by USD 100 million, generating a CHF 90 million gain in Q1 2025.
TRYVIO/JERAYGO Approvals and Clinical Differentiation
Aprocitentan (TRYVIO/JERAYGO) received approvals in the U.S., EU and additional markets; REMS requirement removed in March 2025; incorporated into updated ACC/AHA hypertension guidelines in August 2025. Pivotal PRECISION trial demonstrated double‑digit BP reduction of 15.4 mmHg in 4 weeks with favorable safety profile.
Early Real-World Uptake for TRYVIO
TRYVIO is being prescribed at >25 top hypertension centers during prelaunch activities, with increasing new patient starts and improving refill rates; smooth prior authorization reported for target segments.
Pipeline Progress and Clear Regulatory Path for Lucerastat
Advanced three chemokine receptor antagonists into clinical testing (CCR6 enrolling in psoriasis; CXCR7 study in-progress with MS to start; CXCR3 for vitiligo planned). Established an agreed development plan with regulators for lucerastat in Fabry disease, including a pivotal baseline-controlled biopsy study and a switch study, aiming for potential NDA submission as early as 2029.
QUVIVIQ Global Market Expansion & Local Wins
Public reimbursement wins in multiple markets (France, Germany, U.K., private insurance in Switzerland and Canada) and additional reimbursments (Austria, Germany premium price, negotiations in Quebec); strong demand in Q4 2025 with demand increases of 25% in Germany, 38% in Canada and 45% in the U.K. (quarterly comparisons). Significant uptake in China via partner Simcere with 300k–400k patients treated in first 6 months in private setting.
Pediatric Daridorexant Study Completed
Recruitment completed for pediatric (age 10–18) daridorexant trial; data expected early Q2 2026 — potential to be the first pediatric insomnia treatment and to support U.S. safety halo relevant for descheduling efforts.
Negative Updates
Still Operating at a Loss
Despite substantial improvement, company remains unprofitable: non‑GAAP operating loss of CHF -100 million and U.S. GAAP net loss of CHF -112 million in 2025. Financial expenses were CHF 72 million, including a CHF 61 million noncash expense tied to convertible bond restructuring.
U.S. Commercial Challenges for QUVIVIQ
U.S. sales were flat in 2025 despite overall growth and significant reductions in sales & marketing costs. QUVIVIQ remains Schedule IV in the U.S., creating distribution/friction issues (pharmacies not always stocking) and reliance on descheduling and a label‑enhancing study to materially expand access.
Descheduling Uncertain and Dependent on DEA Process
Descheduling progress awaits DEA public comment period; outcome timing uncertain. Company is pursuing multiple mitigants (label study, DTP pilot), but regulatory uncertainty remains a material U.S. access risk.
TRYVIO Partnership Not Yet Finalized
Active partnership discussions ongoing for TRYVIO/JERAYGO; prior exclusivity arrangement did not close (USD 35 million fee recognized but no deal), leaving commercialization scaling dependent on finding the right partner and complicating launch resourcing.
Cash Runway and Funding Constraints Remain
Year-end cash position (CHF 89 million) plus CHF 80 million facility access provides CHF 169 million liquidity and is described as sufficient to reach next inflection points, but headroom beyond those milestones and funding needs for multiple R&D programs remain uncertain and dependent on partnerships/milestones.
Long Development Timelines and Some Unpowered Studies
Lucerastat pathway to registration targets potential NDA in 2029; the planned renal eGFR study was not requested to be powered for eGFR by FDA (company noted it was not designed to deliver statistical significance for eGFR), implying additional regulatory/commercial risk and longer time to revenue.
One-off and Noncash Financial Impacts
Convertible bond restructuring produced CHF 61 million noncash expense and contributed to CHF 72 million financial expenses; these items weigh on reported GAAP losses and create accounting volatility.
Dependence on Partnerships & External Market Factors
Several growth levers (TRYVIO scale, QUVIVIQ broader U.S. access, Latin America/Central & Eastern Europe agreements) depend on partner deals, pricing environments and payer dynamics — areas cited as complex and potentially slowing commercialization.
Company Guidance
Idorsia guided QUVIVIQ sales of around CHF 200 million for 2026 (up from CHF 134M in 2025, which exceeded the prior guidance of CHF 130M) and said 2026 OpEx (including COGS) will be flat versus 2025, a combination it expects to produce the company’s first positive commercial contribution and drive overall losses lower toward profitability and cash‑flow breakeven. For 2025 the company reported net revenue of CHF 214M (including CHF 134M QUVIVIQ product sales), non‑GAAP contract revenue CHF 72M, a non‑GAAP operating loss improved to CHF ‑100M (from CHF ‑308M in 2024), U.S. GAAP EBIT loss CHF ‑33M and U.S. GAAP net loss CHF ‑112M; cost rationalization saved >CHF 80M and a Viatris negotiation (USD 100M reduction in cost‑sharing) produced a CHF 90M gain. Liquidity at year‑end was CHF 89M with access to a further CHF 80M (total CHF 169M) after drawing CHF 70M of a CHF 150M facility and raising CHF 68M net from equity, and management said it will limit guidance to the one‑year horizon given multiple upcoming inflection points (descheduling, partnerships and pipeline readouts).Idorsia Ltd Financial Statement Overview
Summary
Operating performance is improving (losses and cash burn narrowed materially into 2025), but financial risk remains high due to heavy leverage and persistently negative equity. Cash flow is still negative, implying continued reliance on external funding capacity.Income Statement
Revenue remains modest and volatile, with growth swinging sharply year to year (up strongly in 2022–2023, then down in 2024–2025). Losses are persistent across the full period, but profitability has improved materially from very deep losses in 2021–2022 to a much smaller net loss in 2025. Gross profitability is unusually strong in 2023 and 2025 (while 2024 shows a sharp gross loss), indicating inconsistent cost structure and limited earnings stability despite the recent narrowing of losses.34
Negative
Balance Sheet
Leverage is the central balance-sheet risk. Total debt is high versus the asset base (about 1.27B debt against ~0.47B assets in 2025), and shareholder equity has turned deeply negative since 2022 and remains negative in 2025, signaling a weakened capital cushion. While the debt level is broadly stable over recent years, the negative equity profile and elevated leverage leave limited flexibility if operating performance weakens or refinancing conditions tighten.18
Very Negative
Cash Flow
Cash generation remains pressured: operating cash flow and free cash flow are negative every year shown. That said, cash burn has improved meaningfully, with free cash flow loss narrowing from roughly -0.64B (2023) and -0.37B (2024) to about -0.17B in 2025, consistent with a company moving toward better cash discipline. Despite the improvement, the business still relies on external funding capacity given ongoing negative operating cash flow.22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 221.00M | 112.51M | 152.39M | 97.10M | 35.35M |
| Gross Profit | 199.67M | -67.08M | 145.24M | 90.84M | 17.32M |
| EBITDA | -45.49M | -319.49M | -254.55M | -783.09M | -588.84M |
| Net Income | -112.00M | -263.76M | -297.92M | -827.90M | -634.60M |
Balance Sheet | |||||
| Total Assets | 465.88M | 505.89M | 500.00M | 904.18M | 1.48B |
| Cash, Cash Equivalents and Short-Term Investments | 87.24M | 124.36M | 157.82M | 476.32M | 1.04B |
| Total Debt | 1.27B | 1.26B | 1.20B | 1.23B | 1.16B |
| Total Liabilities | 1.60B | 1.72B | 1.47B | 1.57B | 1.38B |
| Stockholders Equity | -1.14B | -1.21B | -968.72M | -660.96M | 104.20M |
Cash Flow | |||||
| Free Cash Flow | -167.05M | -373.23M | -638.69M | -886.17M | -620.83M |
| Operating Cash Flow | -153.23M | -370.23M | -629.30M | -859.11M | -589.89M |
| Investing Cash Flow | 4.16M | 305.06M | 632.61M | 743.90M | -53.26M |
| Financing Cash Flow | 132.14M | 26.11M | -197.00K | 162.31M | 604.15M |
Idorsia Ltd Technical Analysis
Negative
3.14
Price Trends
3.70
Negative
3.64
Negative
3.29
Negative
Market Momentum
-0.15
Positive
38.92
Neutral
20.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:IDIA, the sentiment is Negative. The current price of 3.14 is below the 20-day moving average (MA) of 3.67, below the 50-day MA of 3.70, and below the 200-day MA of 3.29, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 38.92 is Neutral, neither overbought nor oversold. The STOCH value of 20.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:IDIA.
Idorsia Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | CHF615.24M | 16.63 | ― | ― | 58.51% | ― | |
67 Neutral | CHF324.26M | -487.07 | ― | ― | 744.64% | ― | |
56 Neutral | CHF957.54M | 498.59 | -7.82% | ― | 104.01% | 33.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | CHF204.05M | -0.98 | -301.13% | ― | -56.85% | -186.55% | |
45 Neutral | CHF788.18M | -8.17 | ― | ― | 229.23% | 63.47% | |
45 Neutral | CHF149.39M | -2.50 | -51.05% | ― | -100.00% | 14.45% |
* Healthcare Sector Average
CH:IDIA
Idorsia Ltd
3.14
2.07
194.09%
CH:MOLN
Molecular Partners AG
3.70
0.14
3.93%
CH:BSLN
Basilea Pharmaceutica
50.50
2.45
5.10%
CH:KURN
Kuros Biosciences
24.44
4.98
25.59%
CH:NWRN
Newron Pharmaceuticals SpA
15.62
7.11
83.55%
CH:SANN
Santhera Pharmaceuticals Holding
14.54
-0.14
-0.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.